Phase 2 Oesophageal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with cancer of the gastroesophageal junction (where the stomach meets the food pipe) or esophagogastric cancer, confirmed by a laboratory test of tissue or cells from a specific network of institutions, and the cancer must be at a certain stage of local spread (T3/T4 or involving nearby lymph nodes over 1 cm or showing up on a specific type of scan).
• People aged 18 or older — there is no upper age limit.
• People who are generally able to carry out daily activities with no or minimal limitations, as assessed by a doctor using a standard scale (ECOG score of 0 or 1).
• People with a life expectancy of more than 3 months.
• People whose blood counts, liver function, and kidney function fall within acceptable ranges as measured by blood tests (confirm with trial site for exact values).
• People who are willing and able to use effective contraception (such as hormonal or barrier methods, or abstinence) throughout the study and for 30 days after the last dose of study treatment — this applies to both women who could become pregnant and to men.
• Women who could become pregnant must have a negative pregnancy test (urine or blood) before joining.
• People who are able to understand the study information and are willing to sign a consent form.

Who may not be able to join:

• People whose cancer has spread to distant parts of the body (metastatic disease), as shown on scans done within six weeks of joining (some distant lymph node involvement may be allowed if it falls within the treatment area — confirm with trial site).
• People who have already received chemotherapy, targeted therapy, biological therapy, or radiation treatment for this particular cancer.
• People who have been treated for another serious (invasive) cancer within the last five years, where the chance of that cancer coming back is greater than 5% — though certain non-invasive skin cancers and early-stage surface cancers are generally acceptable.
• People who have taken part in another clinical trial and received an experimental treatment within the 4 weeks before starting this study.
• People with serious heart or lung conditions that are not well controlled, or who have had a heart attack within the past 12 months, or who currently have an active infection with fever.
• People with a history of uncontrolled seizures, significant nervous system disorders, or psychiatric conditions that a doctor judges could affect their ability to consent or follow the study requirements.
• People who are currently pregnant or breastfeeding, as the treatments used in this trial carry known risks to unborn babies and potential risks to nursing infants.
• People who have had major surgery (not including keyhole/laparoscopic procedures) within 4 weeks before starting the study and have not fully recovered.
• People currently taking the medication cimetidine (a type of stomach acid medicine), as it can interfere with one of the study drugs — a different acid-reducing medicine may be substituted before joining (confirm with trial site).
• People with an existing blood-clotting disorder that is not under control.
• People who have previously received a type of chemotherapy drug called a fluoropyrimidine as a systemic (whole-body) treatment, unless it was given as a follow-up (adjuvant) treatment and finished at least six months ago — previous use of fluoropyrimidine creams or skin treatments is generally acceptable.
• People with a known allergy or serious reaction to the drug 5-fluorouracil, or who are known to have a specific enzyme deficiency (DPD deficiency) that affects how this drug is processed by the body.
• People with a history of allergic reactions to drugs chemically similar to 5-fluorouracil, irinotecan, or oxaliplatin — three of the drugs used in this trial.

Important: Always verify eligibility with the trial site directly before applying.